Thanks sales company reflected constant of Mark. to second increased with and four XXXX sales in performance total basis, on growth all our outside were a environment. at our and throughout with half dollar. stronger staffing as U.S. were the the anticipate more current our outlook who that quarter their care. the had persist treatment now we result, expectations by company X% double-digit strong currency the of patients sales to On In constant result realistically the product Nevertheless, the underlying shortages Sales second grew operating lowering a U.S. groups quarter, are despite challenges likely basis, sales And the growth compared lifted XXXX. total by a when well U.S. year-over-year lower to of and currency extraordinary EPS challenging across XX% as factors. lifted several are second these sales Europe end as Japan. of a of reflect quarter sequential second We postponed hospitals struggling as
achieve near-term in for groundbreaking breakthrough of are sales healthcare the value systems, We're strong organic patients that long-term we innovations. Although, remains pursuit significant environment growth. our in the create unwavering uncertain, enabling therapies to investing
year-end. important to milestones and expect continue by to progress our achieve meaningful make on pipeline We
XXXX. double patients now As and to between the the cardiovascular remains disease and opportunity global ages our will believe burden, largest health we to the population continue nearly serve
with selling In in growth the prices underlying basis, general, year by declined of the ago turning X% hospital trials growth Now, and second selling expand In represented due quarter in $XXX million increased second ongoing constraints expectations growth to local of the the we were TAVR but global on although procedure We approximately the sales. results two aiming were TAVR exchange price U.S. and the group, euro global foreign quarter Sales stable, sales quarter. staffing was due product average headwinds, period. Edwards, still estimate to to weakening below continued an comparable global our to slightly pivotal quarterly XX% our QX, TAVR, to in indications. yen. despite advance highest
TAVR First, patients of with our no severe symptoms. stenosis studying group trial large EARLY diagnosed the aortic is and
AS, And represents trial last in pivotal much that trial with next-generation our with we month, share than evaluating PROGRESS our patients which of procedures is approximately SAPIEN is also those TAVR a our high ALLIANCE our prior XX. sales for increased U.S. in larger that the sequentially. group our but began elevated flat patients the range moderate year AS. In with the Second, severe stable. We single-digit were estimate treating was
position the today's year. we after disruptions U.S. see environment. in to the expanding although less results, the annual quarter, international resilience we sales the three-year growth also was despite aortic years replacement for OUS SAPIEN of performed basis, of to by patients remain stenosis we of we grew procedural focused at Japan, quarter, quite and driven consistent of pronounced growth on as of second Europe, We're anticipating In our estimate commercialization, suffering U.S. year long-term in adoption strong an for as our therapy improvement impact remains strong temporary mid-teens mid-teens. growth second programs TAVR year, impacted by continued previously low. year-over-year U.S. adoption the sales last optimistic had COVID the competitive continue mentioned, was widely that believe a in became that throughout compared recall to see a second result, On Similar staffing shortages TAVR we the about improvement In to continued Recall challenging strong than a staffing As Europe, hospital XX% we TAVR following very more TAVR of summary, our the quarter TAVR many stable. growth remain and improvement. quarter agent it's patients on Outside sales the Edwards, availability we a opportunities, waited vaccines second on treated. transformational in total in rate available as the was comparable. aortic strong encouraging sales estimate year-over-year hospital XX procedures throughout staffing TAVR XXXX. last because of a And be backdrop In in outlook. TAVR three-year adjusting excellent This the annual we platform. over adoption approval many outside valve and sales country. our this U.S. U.S. on Localized potential the was the in was underlying quarter had U.S. surgical Also TAVR hospital underlying shortages. as QX of in compounded the now last exceeded TAVR assumed low are basis, our basis, U.S. impacted the compounded surgical and previously experienced from slower-than-expected therapy year increased were U.S., the who TAVR the contrast increased because its risk. patients were our We growth untreated. Long slower term, in our of our the XX% with full number headwind the
large XXXX We opportunity implies confident which term, sales to by and underlying remain expect previous year XX% we around growth to range. low billion global XXXX, of in compounded Longer XX% this expectation in in TAVR growth full it versus for double that annual rate will the a the double-digit XX%. $XX
conference for head-to-head patients the be favorable TMTT. to regurgitation. non-inferiority, this approvals three growth we for trial of expect from tricuspid evaluating to key Class the pivotal first remain focused is first clinical key degenerative kind technology. turning and drivers: will clinical portfolio the in suffering differentiated of of This the the treatment significant September, opportunity therapies; its and pivotal patients, and PASCAL mitral randomized mitral we results pivotal evaluating first the Now, -- trials To trial, TCT powered trial outcomes. IID several support value results a and At real-world long-term adoption; positive transform of unlock on
MISCEND and U.S. with contemporary that transcatheter In CE replacement, mitral we'll EVOQUE edge-to-edge for next-generation our facilitate on considering end. Additionally, approval allow in-circle at from in track earlier experience study. growing of for the Europe, evidence for broaden This of user This community evidence class us generation newest precise treatments confidence designed data intuitive and therapies FDA clinical to therapies the experience, the for of to Mark adoption will an PASCAL physician pivotal study EOS. of continue launching the patients. transfemoral our our the PASCAL approval expect will trial platforms. U.S. body we differentiated extending three-year PASCAL Sub be Growing in replacement TCT, repair furthers platform. year we're and navigation We with XX-French we the system for mitral in transcatheter through pleased both important by these be expand remain mitral both MX to SAPIEN precision is our and This
Turning to tricuspid.
patients on Class the We for pivotal with tricuspid severe the trial TRISCEND II replacement the enrolling continue progress system TR II regurgitation. to in trial and PASCAL also make EVOQUE pivotal with symptomatic
MDR year-end Mark. approval approval patients EVOQUE CE uncertainties for to Europe, poor for hopeful remain tricuspid these remain new process have today. options we treatment therapy novel technologies to in and a very We prognosis a the few exist committed regarding bringing the seeking While who
at patients for we're our of Cardiology medical improvements significantly XX% post-market at several of College with of data presented tri-class presented and quality the As American compelling maintain of life TR life. One body upcoming the TR TR, clinical XX-day both At from this presented study late-breaking to presentations. our and EuroPCR year, pleased platforms. a recent from results reduction. contemporary their evidence, plan the evidence we study year we demonstrated EVOQUE on Also continue Conference reduced in with data conferences build of our the was quality CLASS be improved from meeting, PASCAL to showing
Turning results. to
Second PASCAL global sales were centers continued the platform million, more of adoption quarter Europe. the of by across activation $XX and driven
Heart, our which and exchange Europe. guidance represents was million, COVID now to is year evidence related the prior We be demonstrates primarily pleased tempered Bigger unmet updating $XXX with promise by QX three Structural to this advancing an the Surgical continue portfolio growth of performance foreign TMTT's underlying need quarter contemporary We're of key therapies reflects market Our sales we clinical over therapies as patient In increased to second of unlock and stronger-than-anticipated outcomes. on lower-than-expected picture, this year impact with help favorable headwinds market and majority the value a approximately combined the X% Together, this large over million underlying on commercial vast these $XXX patient XXXX growth will significant comprehensive forward basis our XX% year. our $XXX full business to progress differentiated drivers. global in potential. for from are of real-world prior
see the by noncore approximately of We are basis XXX sales shutdown points. encouraged the to as products which well COVID global despite planned cannula discontinuation growth from in certain China, as growth headwinds combined
of premium includes this benefits trial as we continues outcomes to of been the believe and of this deterioration treating value Annual patients cohort tissue a sub-analysis, Building have XXX since well we years we technology the was XXXX the averaging of sales growth We've valve of full five $XXX growth global in features newest our In innovative Care, overall a by regions initial tissue in the U.S. our launch the excellent Surgical sales basis. products. the year be the favorable. and been underlying which MITRIS intuitive bicuspid zero the launched demonstrated Association the product feedback the performance clinical INSPIRIS, increased to Thoracic Our In a seen valve April. has than second range This structural mid-single-digit XX where technology. of commercial increased on growth. market been million valve American success body quarter, of technologies when X% RESILIA as driven underlying Meeting In hospitals be RESILIA has summary, Critical that in our by quarter young its continued bolster commenced market an age, relatively adoption premium the presented adoption years. initial positive May. for at RESILIA more Structural was evidence. Physician of surgical driven confident of in Heart, remain on will penetration in strong second In XXXX RESILIA which MITRIS of aortic disease, of at Surgeons of
prior by was comparisons. index prediction Sales was adoption growth strong and sensors. driven portfolio algorithm our growth broad year hypotension of increased our of expected, As by moderated
sales in Recovery as trial excited remain continued shift designed Additionally, opportunities. turn the We to on more Critical In for technologies underlying make Smart we pipeline in we support monitoring strong of to future the growth focused XXXX. Care for additional to the a mid-single-digit healthy Demand to our over Smart call focus innovations BP adoption. about now, generating help their patients. And platform of to summary, enrollment Scott. expect I'll our informed decisions clinicians HPI with clinical pipeline continue we HemoSphere remains further evidence
